Questions a plan sponsor actually asks.
What is Daratumumab and Hyaluronidase-Fihj (Human Recombinant) used for?
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) is a CD38-directed Cytolytic Antibody medication tracked in Medicare Part D.
Is there a generic for Daratumumab and Hyaluronidase-Fihj (Human Recombinant)?
No. Daratumumab and Hyaluronidase-Fihj (Human Recombinant) is brand-only with no generic equivalents currently in market.
How much does my plan pay for Daratumumab and Hyaluronidase-Fihj (Human Recombinant)?
NADAC pricing data not currently available for this drug.
Is Daratumumab and Hyaluronidase-Fihj (Human Recombinant) on the FDA shortage list?
No. Daratumumab and Hyaluronidase-Fihj (Human Recombinant) is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.